Tyrosine Kinase Inhibitors: all 10,744 studies that test it
Page 106 of 108. Open to participants first (1,949), then studies with results posted, then the rest; newest registration first within each.
- Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaTerminatedNCT00101088Phase 1
- Gefitinib in Treating Patients With Locally Advanced Esophageal CancerCompletedNCT00100945Phase 2
- Phase I (PH I) Mad Refractory Solid Tumor StudyCompletedNCT00099606Phase 1
- Lapatinib in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT00099060Phase 1/2
- Genistein in Preventing Breast or Endometrial Cancer in Healthy Postmenopausal WomenCompletedNCT00099008Phase 1
- Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck CancerCompletedNCT00098631Phase 2
- Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney CancerTerminatedNCT00098618Phase 2
- Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain MetastasesCompletedNCT00098605Phase 2
- Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00098540Phase 2
- CCI-779 and EKB-569 in Treating Patients With Advanced Solid TumorsCompletedNCT00098501Phase 1
- Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung CancerWithdrawnNCT00098462Phase 1/2
- S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00096512Phase 2
- Sorafenib in Treating Patients With Metastatic Breast CancerCompletedNCT00096434Phase 2
- Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian CancerCompletedNCT00096395Phase 2
- CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerCompletedNCT00096239Phase 2
- Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerCompletedNCT00095966Phase 2
- Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid CancerTerminatedNCT00095693Phase 2
- Lapatinib in Treating Patients With Recurrent or Metastatic Prostate CancerCompletedNCT00095667Phase 2
- BMS-599626 in Patients With Advanced Solid MalignanciesCompletedNCT00095537Phase 1
- BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid TumorsCompletedNCT00095459Phase 1
- A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)CompletedNCT00095225Phase 2
- Study Evaluating AMG 706 in Subjects With Advanced Solid TumorsCompletedNCT00093873Phase 1
- Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal CancerTerminatedNCT00093652Phase 1/2
- Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib MesylateCompletedNCT00093639Phase 1/2
- Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal CancerCompletedNCT00093626Phase 2
- Sorafenib in Treating Patients With Recurrent or Progressive Malignant GliomaCompletedNCT00093613Phase 1
- Sorafenib in Treating Patients With Metastatic or Recurrent Prostate CancerCompletedNCT00093457Phase 2
- Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung CancerCompletedNCT00092001Phase 2
- A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00091663Phase 3
- Gefitinib After Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerTerminatedNCT00091156Phase 3
- Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By SurgeryTerminatedNCT00091078Phase 2
- Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung CancerWithdrawnNCT00090675Phase 3
- Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs)CompletedNCT00089960Phase 2
- Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00088959Phase 1
- Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder CancerCompletedNCT00088946Phase 2
- Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)CompletedNCT00088283Phase 2
- PTK 787 and Gleevec in Patients With AML, AMM, and CML-BPCompletedNCT00088231Phase 1/2
- Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)CompletedNCT00088192Not applicable
- Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)CompletedNCT00087763Phase 2
- S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung CancerCompletedNCT00087412Phase 2
- Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal CancerTerminatedNCT00087334Phase 1/2
- Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical ResectionTerminatedNCT00087269Phase 2
- Docetaxel and Erlotinib in Treating Older Patients With Prostate CancerCompletedNCT00087035Phase 2
- Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT00086879Phase 2
- Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid TumorsCompletedNCT00086528Phase 1
- Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid TumorsCompletedNCT00085553Phase 1
- Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell FibroblastomaCompletedNCT00085475Phase 2
- Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung CancerCompletedNCT00085280Not applicable
- Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008CompletedNCT00084825Phase 2
- Gefitinib and Docetaxel in Treating Patients With Advanced Solid TumorsCompletedNCT00084786Phase 1
- Calcitriol and Gefitinib With or Without Dexamethasone in Treating Patients With Advanced Solid TumorsCompletedNCT00084708Phase 1
- Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma ProtuberansCompletedNCT00084630Phase 2
- Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing CancerCompletedNCT00084513Phase 1
- N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk NeuroblastomaCompletedNCT00084422Phase 1
- Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and NeckCompletedNCT00083057Phase 1
- Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the BreastTerminatedNCT00082667Phase 2
- Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00081926Phase 4
- A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell CarcinomaCompletedNCT00081614Phase 2
- Study of CEP-701 in Treatment of Prostate CancerCompletedNCT00081601Phase 2
- Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaCompletedNCT00081133Phase 1/2
- Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone MetastasesCompletedNCT00080678Phase 2
- Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast CancerCompletedNCT00080665Phase 1
- Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT00080340Phase 3
- Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory CancerCompletedNCT00079612Phase 2
- Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous LeukemiaCompletedNCT00079313Phase 2
- Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and NeckCompletedNCT00079053Phase 1
- Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast CancerCompletedNCT00078572Phase 3
- A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.CompletedNCT00078000Phase 2
- Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.CompletedNCT00077987Phase 2
- Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid TumorsCompletedNCT00077454Phase 1
- Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast CancerCompletedNCT00077025Phase 2
- Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine TumorsCompletedNCT00075439Phase 2
- Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube CancerCompletedNCT00074867Phase 2
- A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With ChemotherapyCompletedNCT00074854Phase 1/2
- Study Evaluating EKB-569 in Advanced Colorectal CancerCompletedNCT00072748Phase 2
- Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung CancerCompletedNCT00072631Phase 2
- Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00072072Phase 1
- Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)CompletedNCT00071994Phase 2
- ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)CompletedNCT00071188Phase 2
- S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell CancerCompletedNCT00068783Phase 2
- Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung CancerCompletedNCT00068653Phase 2
- Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerCompletedNCT00068497Not applicable
- Study Evaluating EKB-569 in Advanced Non-Small Cell Lung CancerCompletedNCT00067548Phase 2
- Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast CancerCompletedNCT00066378Phase 2
- Gefitinib in Treating Patients With Metastatic Breast Cancer That Has Progressed After Antiestrogen and Nonsteroidal Aromatase Inhibitor TherapyCompletedNCT00066339Phase 2
- Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00066326Phase 1
- ZD6474 in Treating Patients With Small Cell Lung CancerCompletedNCT00066313Phase 2
- Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML)CompletedNCT00064584Phase 1
- Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic CancerCompletedNCT00064285Phase 1
- BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib MesylateCompletedNCT00064233Phase 1
- Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic CancerCompletedNCT00063947Phase 1
- Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and NeckCompletedNCT00063895Phase 1/2
- GW572016 For Treatment Of Refractory Metastatic Breast CancerCompletedNCT00062686Phase 2
- Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung CancerCompletedNCT00062270Phase 1/2
- Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell TumorCompletedNCT00062205Phase 2
- A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal CancerCompletedNCT00060411Phase 1
- Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell CancerCompletedNCT00060307Phase 2
- GW786034 in Treating Patients With Advanced Solid TumorsCompletedNCT00060151Phase 1
- Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a TaxaneCompletedNCT00059852Phase 2
- This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.CompletedNCT00059722Phase 2